Isolation of CD4+CD25+ regulatory T cells for clinical trials.
Biol Blood Marrow Transplant
; 12(3): 267-74, 2006 Mar.
Article
en En
| MEDLINE
| ID: mdl-16503495
ABSTRACT
The adoptive transfer of donor CD4+CD25+ regulatory T cells has been shown to protect from lethal graft-versus-host disease after allogeneic bone marrow transplantation in murine disease models. Efficient isolation strategies that comply with good manufacturing practice (GMP) guidelines are prerequisites for the clinical application of human CD4+CD25+ regulatory T cells. Here we describe the isolation of CD4+CD25+ T cells with regulatory function from standard leukapheresis products by using a 2-step magnetic cell-separation protocol performed under GMP conditions. The generated cell products contained on average 49.5% CD4+CD25high T cells that phenotypically and functionally represented natural CD4+CD25+ regulatory T cells and showed a suppressive activity comparable to that of CD4+CD25+ regulatory T-cell preparations purified by non-GMP-approved fluorescence-activated cell sorting.
Buscar en Google
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Leucaféresis
/
Linfocitos T Reguladores
/
Traslado Adoptivo
/
Enfermedad Injerto contra Huésped
Tipo de estudio:
Etiology_studies
/
Guideline
/
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Biol Blood Marrow Transplant
Asunto de la revista:
HEMATOLOGIA
/
TRANSPLANTE
Año:
2006
Tipo del documento:
Article
País de afiliación:
Alemania